Year To Quarter End Consolidated Statement Of Income

Daito Pharmaceutical Co., Ltd. - Filing #7542348

Concept 2023-06-01 to
2023-08-31
2022-06-01 to
2022-08-31
Year to quarter end consolidated statement of income
Statement of income
Net sales
12,178,000,000 JPY
12,041,000,000 JPY
Cost of sales
9,703,000,000 JPY
9,263,000,000 JPY
Gross profit (loss)
2,474,000,000 JPY
2,777,000,000 JPY
Selling, general and administrative expenses
Selling, general and administrative expenses
1,393,000,000 JPY
1,275,000,000 JPY
Operating profit (loss)
1,080,000,000 JPY
1,501,000,000 JPY
Non-operating income
Interest income
0 JPY
0 JPY
Dividend income
32,000,000 JPY
30,000,000 JPY
Non-operating income
42,000,000 JPY
36,000,000 JPY
Non-operating expenses
Interest expenses
3,000,000 JPY
3,000,000 JPY
Non-operating expenses
30,000,000 JPY
62,000,000 JPY
Ordinary profit (loss)
1,092,000,000 JPY
1,475,000,000 JPY
Extraordinary losses
Extraordinary losses
0 JPY
4,000,000 JPY
Profit (loss) before income taxes
1,092,000,000 JPY
1,470,000,000 JPY
Income taxes
429,000,000 JPY
544,000,000 JPY
Profit (loss)
663,000,000 JPY
926,000,000 JPY
Profit attributable to
Profit (loss) attributable to non-controlling interests
-20,000,000 JPY
-19,000,000 JPY
Profit (loss) attributable to owners of parent
683,000,000 JPY
946,000,000 JPY
Other comprehensive income
Valuation difference on available-for-sale securities
118,000,000 JPY
210,000,000 JPY
Foreign currency translation adjustment
37,000,000 JPY
82,000,000 JPY
Remeasurements of defined benefit plans, net of tax
-25,000,000 JPY
19,000,000 JPY
Other comprehensive income
130,000,000 JPY
312,000,000 JPY
Comprehensive income
793,000,000 JPY
1,238,000,000 JPY
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
804,000,000 JPY
1,235,000,000 JPY
Comprehensive income attributable to non-controlling interests
-10,000,000 JPY
2,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.